Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 364 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017, provides an overview of the Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline landscape.

Heart failure is also known as congestive heart failure (CHF). CHF is a condition in which the heart is no longer able to pump out enough oxygen-rich blood. Symptoms include cough, fatigue, weakness, faintness, loss of appetite, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. The predisposing factors include high blood pressure, diabetes, sleep apnea, alcohol use and irregular heartbeats. Treatment includes surgery, vasodilator, beta blockers and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 18, 28, 16, 2, 32, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 19 and 8 molecules, respectively.

Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Congestive Heart Failure (Heart Failure) - Overview 11
Congestive Heart Failure (Heart Failure) - Therapeutics Development 12
Pipeline Overview 12
Pipeline by Companies 13
Pipeline by Universities/Institutes 19
Products under Development by Companies 22
Products under Development by Universities/Institutes 29
Congestive Heart Failure (Heart Failure) - Therapeutics Assessment 32
Assessment by Target 32
Assessment by Mechanism of Action 37
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development 46
Allosteros Therapeutics Inc 46
Amgen Inc 46
Anexon Inc 47
AnGes MG Inc 47
Araim Pharmaceuticals Inc 48
Arbor Pharmaceuticals LLC 48
Ascelegen Therapeutics Inc 49
AstraZeneca Plc 49
Athersys Inc 50
Bayer AG 50
BEAT BioTherapeutics Corp 51
BioCardia Inc 51
Boehringer Ingelheim GmbH 52
Bristol-Myers Squibb Company 52
Capricor Therapeutics Inc 53
Celixir Ltd 53
Celyad SA 54
Daiichi Sankyo Company Ltd 54
F. Hoffmann-La Roche Ltd 55
FibroGen Inc 55
GlaxoSmithKline Plc 56
Heart Metabolics Ltd 56
Hemostemix Ltd 57
Innopharmax Inc 57
Intrexon Corp 58
Jiangsu Hengrui Medicine Co Ltd 58
Juventas Therapeutics Inc 59
La Jolla Pharmaceutical Company 59
Lead Discovery Center GmbH 60
Lee's Pharmaceutical Holdings Ltd 60
Les Laboratoires Servier SAS 61
Lonestar Heart Inc 61
Madeleine Pharmaceuticals Inc 62
Mast Therapeutics Inc 62
Merck & Co Inc 63
Mesoblast Ltd 63
MorphoSys AG 64
NanoCor Therapeutics Inc 64
Neurocrine Biosciences Inc 65
Novartis AG 65
Nuo Therapeutics Inc 66
Nyken BV 66
Orion Oyj 67
Palatin Technologies Inc 67
PharmaIN Corp 68
PhaseBio Pharmaceuticals Inc 68
Quantum Genomics SA 69
Recardio GmbH 69
RedHill Biopharma Ltd 70
Renova Therapeutics Inc 70
scPharmaceuticals Inc 71
Stealth BioTherapeutics Inc 71
Stemedica Cell Technologies Inc 72
Target Heart Biotec Srl 72
Theravance Biopharma Inc 73
TiGenix NV 73
Torrent Pharmaceuticals Ltd 74
Trevena Inc 74
U.S. Stem Cell Inc 75
Vicore Pharma AB 75
Zensun (Shanghai) Sci & Tech Co Ltd 76
Congestive Heart Failure (Heart Failure) - Drug Profiles 77
(hydralazine + isosorbide dinitrate) XR - Drug Profile 77
(sacubitril + valsartan) - Drug Profile 78
AAVS-100A1 - Drug Profile 85
ACP-01 - Drug Profile 87
AdipoCell - Drug Profile 90
AE-07 - Drug Profile 93
AK-10 - Drug Profile 94
aladorian sodium - Drug Profile 95
ALD-201 - Drug Profile 97
AMG-986 - Drug Profile 99
AntimiR-199a - Drug Profile 100
Antisense RNAi Gene Therapy to Inhibit ANGPTL2 for Heart Failure - Drug Profile 101
ANX-042 - Drug Profile 102
ARX-720 - Drug Profile 103
AZD-4831 - Drug Profile 104
BAY-1753011 - Drug Profile 105
BAY-868050 - Drug Profile 106
BBR-12 - Drug Profile 107
beperminogene perplasmid - Drug Profile 108
BMS-986231 - Drug Profile 114
C-21 - Drug Profile 116
C-Cure - Drug Profile 119
CAP-1002 - Drug Profile 125
Carfostin - Drug Profile 131
carvedilol CR - Drug Profile 132
carvedilol phosphate CR - Drug Profile 134
Cell Therapy for Heart failure - Drug Profile 135
cenderitide - Drug Profile 136
cibinetide - Drug Profile 140
CLR-325 - Drug Profile 143
CTX-101 - Drug Profile 144
dapagliflozin propanediol - Drug Profile 146
Drug to Inhibit Calpain for Right Heart Failure - Drug Profile 153
Drugs to Inhibit miR-425 for Hypertension and Heart Failure - Drug Profile 154
ECRA-1 - Drug Profile 155
elamipretide - Drug Profile 156
empagliflozin - Drug Profile 164
enalapril maleate - Drug Profile 173
FG-6874 - Drug Profile 174
furosemide - Drug Profile 175
GDF-11 - Drug Profile 177
Gene Therapy for Heart Failure - Drug Profile 178
Gene Therapy to Activate Adenylate Cyclase Type 6 for Heart Failure - Drug Profile 179
Gene Therapy to Activate GLP-1 for Congestive Heart Failure - Drug Profile 180
Gene Therapy to Activate HDAC4 for Heart Failure - Drug Profile 181
Gene Therapy to Activate UCn 2 for Congestive Heart Failure - Drug Profile 182
Gene Therapy to Inhibit GRK2 for Heart Failure - Drug Profile 183
Gene Therapy to Target mAKAPbeta for Heart Failure - Drug Profile 184
GSK-2798745 - Drug Profile 185
istaroxime - Drug Profile 186
ITD-1 - Drug Profile 188
ivabradine hydrochloride - Drug Profile 189
ivabradine hydrochloride SR - Drug Profile 192
JVS-100 - Drug Profile 193
K-1062 - Drug Profile 198
KBP-5074 - Drug Profile 199
L-2286 - Drug Profile 201
levosimendan - Drug Profile 202
milrinone ER - Drug Profile 207
Monoclonal Antibody to Activate Sodium Potassium ATPase for Congestive Heart Failure and Status Epilepticus - Drug Profile 208
Monoclonal Antibody to Inhibit Periostin1 for Congestive Heart Failure - Drug Profile 209
MP-3167 - Drug Profile 210
MPC-150IM - Drug Profile 211
MRS-2339 - Drug Profile 216
MyoCell - Drug Profile 217
MyoCell SDF-1 - Drug Profile 219
NBI-69734 - Drug Profile 220
neladenoson bialanate - Drug Profile 221
Neucardin - Drug Profile 222
NM-922 - Drug Profile 225
NP-202 - Drug Profile 226
NPA-7 - Drug Profile 228
NYK-1112 - Drug Profile 229
Oligonucleotides to Antagonise Beta 1 Adrenergic Receptor for Pediatric Heart Failure - Drug Profile 230
omecamtiv mecarbil MR - Drug Profile 231
PB-1046 - Drug Profile 239
Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure - Drug Profile 241
Peptides to Inhibit MyBP-C/Myosin Interaction for Heart Failure - Drug Profile 242
perhexiline maleate - Drug Profile 243
PF-05285401 - Drug Profile 245
PHIN-1138 - Drug Profile 257
pirfenidone - Drug Profile 258
PL-3994 - Drug Profile 265
PL-5028 - Drug Profile 267
poloxamer - Drug Profile 268
pyroglutaminated serpinin - Drug Profile 270
QGC-101 - Drug Profile 271
REC-02 - Drug Profile 272
Recombinant Protein for Congestive Heart Failure - Drug Profile 273
ROMKi-B - Drug Profile 274
RT-100 - Drug Profile 275
RT-110 - Drug Profile 277
RT-300 - Drug Profile 278
RT-400 - Drug Profile 279
S-38844 - Drug Profile 280
serelaxin - Drug Profile 281
serpinin - Drug Profile 286
SG-1002 - Drug Profile 287
Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders - Drug Profile 288
Small Molecule to Inhibit CYP11B2 for Heart Failure - Drug Profile 289
Small Molecules for Diabetes and Congestive Heart Failure - Drug Profile 290
Small Molecules for Diastolic Heart Failure - Drug Profile 291
Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 292
Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 293
Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile 294
Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain - Drug Profile 295
Small Molecules to Inhibit GRK2 for Heart Failure - Drug Profile 296
Small Molecules to Inhibit PDE4 for Heart Failure - Drug Profile 297
Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 298
Small molecules to Inhibit Phosphoinositide 3-Kinase Gamma for Heart Failure, Breast Cancer and Chronic Obstructive Pulmonary Disease - Drug Profile 299
Small Molecules to Inhibit Porcupine for Oncology, Degenerative Disorders And Congestive Heart Failure - Drug Profile 300
Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile 301
Small Molecules to Target Beta 2 Adrenergic Receptor and Cannabinoid Receptor for Oncology, Respiratory and Cardiovascular Disorders - Drug Profile 302
sodium nitrite - Drug Profile 303
SP-20202 - Drug Profile 307
Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 308
Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile 314
Stem Cell Therapy for Congestive Heart Failure and Kawasaki Disease - Drug Profile 315
Stem Cell Therapy for Heart Failure - Drug Profile 316
Stem Cell Therapy for Myocardial Infarction and Heart Failure - Drug Profile 317
Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 318
Synthetic Peptide to Agonize Beta 2 Adrenergic Receptor for Congestive Heart Failure - Drug Profile 319
Synthetic Peptide to Agonize Guanylate Cyclase A for Cardiovascular Disorders - Drug Profile 320
TD-0714 - Drug Profile 321
TD-1439 - Drug Profile 323
TR-4 - Drug Profile 324
TRC-4186 - Drug Profile 325
TRV-120023 - Drug Profile 327
ularitide - Drug Profile 328
valsartan CR - Drug Profile 330
VCP-746 - Drug Profile 331
vericiguat - Drug Profile 332
Xcel-hCardP - Drug Profile 334
Congestive Heart Failure (Heart Failure) - Dormant Projects 335
Congestive Heart Failure (Heart Failure) - Discontinued Products 341
Congestive Heart Failure (Heart Failure) - Product Development Milestones 343
Featured News & Press Releases 343
Appendix 354
Methodology 354
Coverage 354
Secondary Research 354
Primary Research 354
Expert Panel Validation 354
Contact Us 354
Disclaimer 355

List of Tables

Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Allosteros Therapeutics Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Amgen Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Anexon Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by AnGes MG Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Araim Pharmaceuticals Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Arbor Pharmaceuticals LLC, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Ascelegen Therapeutics Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by AstraZeneca Plc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Athersys Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by BioCardia Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Company, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Capricor Therapeutics Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Celixir Ltd, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Celyad SA, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by FibroGen Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by GlaxoSmithKline Plc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Heart Metabolics Ltd, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Hemostemix Ltd, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Intrexon Corp, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Juventas Therapeutics Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by La Jolla Pharmaceutical Company, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Lead Discovery Center GmbH, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Les Laboratoires Servier�SAS, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Lonestar Heart Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Madeleine Pharmaceuticals Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Mast Therapeutics Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Merck & Co Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Mesoblast Ltd, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by MorphoSys AG, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by NanoCor Therapeutics Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Neurocrine Biosciences Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Novartis AG, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Nuo Therapeutics Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Nyken BV, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Orion Oyj, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Palatin Technologies Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by PharmaIN Corp, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by PhaseBio Pharmaceuticals Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Quantum Genomics SA, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Recardio GmbH, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by RedHill Biopharma Ltd, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Renova Therapeutics Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by scPharmaceuticals Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Stealth BioTherapeutics Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Stemedica Cell Technologies Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Target Heart Biotec Srl, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Theravance Biopharma Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by TiGenix NV, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Trevena Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by U.S. Stem Cell Inc, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Vicore Pharma AB, H1 2017
Congestive Heart Failure (Heart Failure) - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2017
Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2017
Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2017 (Contd..2), H1 2017
Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2017 (Contd..3), H1 2017
Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2017 (Contd..4), H1 2017
Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2017 (Contd..5), H1 2017
Congestive Heart Failure (Heart Failure) - Discontinued Products, H1 2017
Congestive Heart Failure (Heart Failure) - Discontinued Products, H1 2017 (Contd..1), H1 2017